

Gaetano Finocchiaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8896376/publications.pdf>

Version: 2024-02-01

158
papers

19,761
citations

31902

53
h-index

11899

134
g-index

164
all docs

164
docs citations

164
times ranked

23622
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477. | 13.5 | 3,979 |
| 2 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498. | 13.9 | 2,582 |
| 3 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6. | 7.7 | 1,282 |
| 4 | Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6. | 7.7 | 836 |
| 5 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385. | 5.1 | 776 |
| 6 | Transforming Fusions of <i>FGFR</i> and <i>TACC</i> Genes in Human Glioblastoma. <i>Science</i> , 2012, 337, 1231-1235. | 6.0 | 716 |
| 7 | Clonal evolution of glioblastoma under therapy. <i>Nature Genetics</i> , 2016, 48, 768-776. | 9.4 | 591 |
| 8 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542. | 5.1 | 582 |
| 9 | The integrated landscape of driver genomic alterations in glioblastoma. <i>Nature Genetics</i> , 2013, 45, 1141-1149. | 9.4 | 524 |
| 10 | Gene therapy of experimental brain tumors using neural progenitor cells. <i>Nature Medicine</i> , 2000, 6, 447-450. | 15.2 | 450 |
| 11 | Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120. | 13.7 | 320 |
| 12 | Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas. <i>Cancer Research</i> , 2006, 66, 10247-10252. | 0.4 | 237 |
| 13 | Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317. | 3.2 | 230 |
| 14 | The landscape of the mesenchymal signature in brain tumours. <i>Brain</i> , 2019, 142, 847-866. | 3.7 | 228 |
| 15 | Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016, 167, 1281-1295.e18. | 13.5 | 207 |
| 16 | Identification of Tumor-Specific Molecular Signatures in Intracranial Ependymoma and Association With Clinical Characteristics. <i>Journal of Clinical Oncology</i> , 2006, 24, 5223-5233. | 0.8 | 194 |
| 17 | Combined analysis of <i>TERT</i> , <i>EGFR</i> , and <i>IDH</i> status defines distinct prognostic glioblastoma classes. <i>Neurology</i> , 2014, 83, 1200-1206. | 1.5 | 176 |
| 18 | Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 79-87. | 0.6 | 172 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949. | 0.6 | 165 |
| 20 | Glioma progression is shaped by genetic evolution and microenvironment interactions. <i>Cell</i> , 2022, 185, 2184-2199.e16. | 13.5 | 163 |
| 21 | TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. <i>British Journal of Cancer</i> , 2014, 111, 2024-2032. | 2.9 | 158 |
| 22 | Molecular characterization of inherited carnitine palmitoyltransferase II deficiency.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 8429-8433. | 3.3 | 151 |
| 23 | The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019, 25, 176-187. | 15.2 | 145 |
| 24 | Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. <i>Clinical Cancer Research</i> , 2007, 13, 2606-2613. | 3.2 | 144 |
| 25 | cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 661-665. | 3.3 | 141 |
| 26 | The "Bystander Effect": Association of U-87 Cell Death with Ganciclovir-Mediated Apoptosis of Nearby Cells and Lack of Effect in Athymic Mice. <i>Human Gene Therapy</i> , 1995, 6, 763-772. | 1.4 | 135 |
| 27 | The <i>MET</i> Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. <i>Cancer Research</i> , 2012, 72, 4537-4550. | 0.4 | 120 |
| 28 | Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884. | 0.6 | 119 |
| 29 | Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. <i>Neuropathology and Applied Neurobiology</i> , 2011, 37, 381-394. | 1.8 | 118 |
| 30 | Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine "DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351. | 0.8 | 110 |
| 31 | B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. <i>EBioMedicine</i> , 2019, 47, 33-43. | 2.7 | 101 |
| 32 | Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 4. | 2.4 | 100 |
| 33 | Constitutive and TNF \pm -inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 96 |
| 34 | A Radial Glia Gene Marker, Fatty Acid Binding Protein 7 (FABP7), Is Involved in Proliferation and Invasion of Glioblastoma Cells. <i>PLoS ONE</i> , 2012, 7, e52113. | 1.1 | 94 |
| 35 | High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray. <i>Molecular Cancer Research</i> , 2009, 7, 665-677. | 1.5 | 91 |
| 36 | Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. <i>Human Molecular Genetics</i> , 1995, 4, 19-29. | 1.4 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma. <i>Cancer Research</i> , 2014, 74, 1833-1844. | 0.4 | 84 |
| 38 | PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. <i>Oncogene</i> , 1998, 16, 541-545. | 2.6 | 79 |
| 39 | DNA Damage in Mammalian Neural Stem Cells Leads to Astrocytic Differentiation Mediated by BMP2 Signaling through JAK-STAT. <i>Stem Cell Reports</i> , 2013, 1, 123-138. | 2.3 | 79 |
| 40 | NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. <i>Oncotarget</i> , 2012, 3, 723-734. | 0.8 | 77 |
| 41 | The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. <i>Oncogene</i> , 2003, 22, 2581-2591. | 2.6 | 76 |
| 42 | <scp>MET</scp> inhibition overcomes radiation resistance of glioblastoma stemâ€like cells. <i>EMBO Molecular Medicine</i> , 2016, 8, 550-568. | 3.3 | 74 |
| 43 | A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. <i>Nature Communications</i> , 2016, 7, 12885. | 5.8 | 72 |
| 44 | AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312. | 0.6 | 71 |
| 45 | Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene. <i>Human Gene Therapy</i> , 1997, 8, 1345-1353. | 1.4 | 69 |
| 46 | Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. <i>Neuro-Oncology</i> , 2014, 16, 719-727. | 0.6 | 68 |
| 47 | Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. <i>Molecular Cancer</i> , 2004, 3, 25. | 7.9 | 66 |
| 48 | Assignment of the Human Carnitine Palmitoyltransferase II Gene (CPT1) to Chromosome 1p32. <i>Genomics</i> , 1994, 24, 195-197. | 1.3 | 65 |
| 49 | Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. <i>Cancer</i> , 2002, 94, 1037-1048. | 2.0 | 65 |
| 50 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. <i>Journal of Immunology Research</i> , 2017, 2017, 1-16. | 0.9 | 61 |
| 51 | Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. <i>Journal of Neurosurgery</i> , 2000, 92, 419-427. | 0.9 | 60 |
| 52 | A role for the transcription factor HEY1 in glioblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 136-146. | 1.6 | 60 |
| 53 | The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>OncolImmunology</i> , 2013, 2, e23401. | 2.1 | 56 |
| 54 | Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8⁺ T cell activation in the presence of adjuvant temozolomide. <i>OncolImmunology</i> , 2018, 7, e1412901. | 2.1 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Increasing complexity of the karyotype in 50 human gliomas. <i>Cancer Genetics and Cytogenetics</i> , 1994, 75, 77-89. | 1.0 | 51 |
| 56 | Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. <i>Neuroscience Letters</i> , 2004, 370, 180-185. | 1.0 | 51 |
| 57 | Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006, 119, 84-90. | 2.3 | 51 |
| 58 | The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2014, 157, 753. | 13.5 | 51 |
| 59 | Resetting cancer stem cell regulatory nodes upon <scp>MYC</scp> inhibition. <i>EMBO Reports</i> , 2016, 17, 1872-1889. | 2.0 | 51 |
| 60 | Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. <i>Stem Cells</i> , 2017, 35, 2218-2228. | 1.4 | 47 |
| 61 | A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528. | 1.9 | 47 |
| 62 | Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. <i>Neurosurgical Review</i> , 2016, 39, 37-46. | 1.2 | 45 |
| 63 | cDNA cloning and mitochondrial import of the beta-subunit of the human electron-transfer flavoprotein. <i>FEBS Journal</i> , 1993, 213, 1003-1008. | 0.2 | 44 |
| 64 | The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. <i>Neurobiology of Disease</i> , 2006, 21, 314-323. | 2.1 | 44 |
| 65 | ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi17-vi18. | 0.6 | 43 |
| 66 | Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 101-109. | 2.0 | 42 |
| 67 | Purification and properties of carnitine acetyltransferase from human liver. <i>FEBS Journal</i> , 1990, 189, 539-546. | 0.2 | 40 |
| 68 | EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 39 |
| 69 | A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1739-1750. | 2.0 | 38 |
| 70 | Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. <i>Neuro-Oncology</i> , 2010, 12, 377-388. | 0.6 | 33 |
| 71 | ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. <i>Cytokine</i> , 2001, 15, 27-38. | 1.4 | 32 |
| 72 | Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002, 52, 842-845. | 2.8 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Rai is a New Regulator of Neural Progenitor Migration and Glioblastoma Invasion. <i>Stem Cells</i> , 2012, 30, 817-832. | 1.4 | 32 |
| 74 | Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting a once adjuvant treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1440-1445. | 0.4 | 31 |
| 75 | Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. <i>Neuro-Oncology</i> , 2007, 9, 298-307. | 0.6 | 31 |
| 76 | Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. <i>Neurological Sciences</i> , 2015, 36, 1431-1440. | 0.9 | 31 |
| 77 | An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e52301. | 1.1 | 30 |
| 78 | Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2005, 74, 87-90. | 1.4 | 29 |
| 79 | Reelin affects chain-migration and differentiation of neural precursor cells. <i>Molecular and Cellular Neurosciences</i> , 2009, 42, 341-349. | 1.0 | 29 |
| 80 | Immunotherapy for glioma. <i>Current Opinion in Neurology</i> , 2011, 24, 641-647. | 1.8 | 29 |
| 81 | VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 499-504. | 1.4 | 29 |
| 82 | Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2013, 8, e74345. | 1.1 | 28 |
| 83 | Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 163, 203-210. | 1.7 | 28 |
| 84 | KLF6 is not the major target of chromosome 10p losses in glioblastomas. <i>International Journal of Cancer</i> , 2004, 111, 640-641. | 2.3 | 27 |
| 85 | Perspectives for immunotherapy in glioblastoma treatment. <i>Current Opinion in Oncology</i> , 2014, 26, 608-614. | 1.1 | 26 |
| 86 | Retroviral-mediated transfer of the galactocerebrosidase gene in neural progenitor cells. <i>NeuroReport</i> , 1998, 9, 3823-2827. | 0.6 | 25 |
| 87 | FABP4 is a candidate marker of cerebellar liponeurocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 108, 513-519. | 1.4 | 25 |
| 88 | 126 novel mutations in Italian patients with neurofibromatosis type 1. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 513-525. | 0.6 | 25 |
| 89 | The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. <i>Oncolmmunology</i> , 2016, 5, e1108513. | 2.1 | 25 |
| 90 | Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , 2021, 9, 441-453. | 1.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1759-1774. | 1.1 | 24 |
| 92 | FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. <i>Oncotarget</i> , 2012, 3, 1146-1157. | 0.8 | 24 |
| 93 | Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. <i>Cancer</i> , 2002, 94, 1037-48. | 2.0 | 24 |
| 94 | Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI11. <i>Neuro-Oncology</i> , 2006, 8, 96-108. | 0.6 | 23 |
| 95 | Molecular Cloning of cDNAs Encoding Human Carnitine Acetyltransferase and Mapping of the Corresponding Gene to Chromosome 9q34.1. <i>Genomics</i> , 1994, 23, 94-99. | 1.3 | 22 |
| 96 | Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. <i>Human Genetics</i> , 1995, 95, 709-11. | 1.8 | 22 |
| 97 | DNA Microarray Analysis Identifies <i>CKS2</i> and <i>LEPR</i> as Potential Markers of Meningioma Recurrence. <i>Oncologist</i> , 2011, 16, 1440-1450. | 1.9 | 22 |
| 98 | Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3T: A phantom study. <i>Physica Medica</i> , 2014, 30, 702-707. | 0.4 | 22 |
| 99 | Altered function of the glutamate-aspartate transporter GLAST, a potential therapeutic target in glioblastoma. <i>International Journal of Cancer</i> , 2019, 144, 2539-2554. | 2.3 | 21 |
| 100 | Brain engraftment and therapeutic potential of stem/progenitor cells derived from mouse skin. <i>Journal of Gene Medicine</i> , 2006, 8, 506-513. | 1.4 | 20 |
| 101 | Radiation-induced glioblastoma in a medulloblastoma patient: A case report with molecular features. <i>Neuropathology</i> , 2008, 28, 633-639. | 0.7 | 20 |
| 102 | High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 831-842. | 2.0 | 20 |
| 103 | Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. <i>Onc Immunology</i> , 2012, 1, 884-893. | 2.1 | 19 |
| 104 | Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in a Large Independent Cohort. <i>Cancers</i> , 2019, 11, 1838. | 1.7 | 19 |
| 105 | Dendritic Cell Vaccines for Cancer Stem Cells. <i>Methods in Molecular Biology</i> , 2009, 568, 233-247. | 0.4 | 19 |
| 106 | Localization of the human gene for carnitine palmitoyltransferase to 1p13-p11 by nonradioactive in situ hybridization. <i>Genomics</i> , 1992, 13, 1372-1374. | 1.3 | 18 |
| 107 | Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CK1 gene in malignant gliomas. <i>International Journal of Cancer</i> , 1995, 62, 115-117. | 2.3 | 18 |
| 108 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. <i>Cell Reports</i> , 2021, 36, 109455. | 2.9 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients. <i>Stem Cells Translational Medicine</i> , 2015, 4, 1164-1172. | 1.6 | 17 |
| 110 | ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5886. | 1.8 | 17 |
| 111 | Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e90535. | 1.1 | 17 |
| 112 | A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e114713. | 1.1 | 17 |
| 113 | Loss of heterozygosity studies in extracranial metastatic meningiomas. <i>Journal of Neuro-Oncology</i> , 2007, 85, 81-85. | 1.4 | 16 |
| 114 | TLRgeting Evasion of Immune Pathways in Glioblastoma. <i>Cell Stem Cell</i> , 2017, 20, 422-424. | 5.2 | 16 |
| 115 | Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz022. | 0.4 | 16 |
| 116 | Genetic signature of adult gliomas and correlation with MRI features. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 709-720. | 1.5 | 15 |
| 117 | Expression profile of frizzled receptors in human medulloblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 106, 271-280. | 1.4 | 14 |
| 118 | Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. <i>Molecular Cancer</i> , 2013, 12, 160. | 7.9 | 14 |
| 119 | Assignment of the Gene Encoding the Î²-Subunit of the Electron-Transfer Flavoprotein (ETFB) to Human Chromosome 19q13.3. <i>Genomics</i> , 1994, 19, 177-179. | 1.3 | 12 |
| 120 | Principles of immunotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181. | 1.0 | 12 |
| 121 | Identification and characterization of a new source of adult human neural progenitors. <i>Cell Death and Disease</i> , 2017, 8, e2991-e2991. | 2.7 | 12 |
| 122 | Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 2007. | 1.0 | 12 |
| 123 | In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. <i>Neurological Sciences</i> , 2020, 41, 347-355. | 0.9 | 12 |
| 124 | A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , 2021, 26, e2254-e2264. | 1.9 | 12 |
| 125 | Isolation and sub-chromosomal localization of a DNA fragment of the human choline acetyltransferase gene. <i>Neuroscience Letters</i> , 1991, 132, 191-194. | 1.0 | 11 |
| 126 | Identification of 5â€² regulatory regions of the human carnitine palmitoyltransferase II gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1994, 1219, 237-240. | 2.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | P53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. <i>Cancer Genetics and Cytogenetics</i> , 1994, 74, 139-143. | 1.0 | 11 |
| 128 | Ultrasonic Surgical Aspirate is a Reliable Source For Culturing Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2016, 6, 32788. | 1.6 | 11 |
| 129 | Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREC randomized phase II study. <i>Oncotarget</i> , 2017, 8, 55575-55581. | 0.8 | 10 |
| 130 | Operability of glioblastomas: "œsins of action" versus "œsins of non-action". <i>Neurological Sciences</i> , 2013, 34, 2107-2116. | 0.9 | 9 |
| 131 | Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study. <i>Cytotherapy</i> , 2017, 19, 721-734. | 0.3 | 9 |
| 132 | Novel mechanisms and approaches in immunotherapy for brain tumors. <i>Discovery Medicine</i> , 2015, 20, 7-15. | 0.5 | 9 |
| 133 | A Recurrent 19q11"12 Breakpoint Suggested by Cytogenetic and Fluorescence In Situ Hybridization Analysis of Three Glioblastoma Cell Lines. <i>Cancer Genetics and Cytogenetics</i> , 1999, 110, 82-86. | 1.0 | 8 |
| 134 | Allergic Signs in Glioma Pathology: Current Knowledge and Future Perspectives. <i>Cancers</i> , 2019, 11, 404. | 1.7 | 7 |
| 135 | Actinomycin D: a new opening for an old drug. <i>Neuro-Oncology</i> , 2020, 22, 1235-1236. | 0.6 | 7 |
| 136 | IL-4 Gene Transfer for the Treatment of Experimental Gliomas. <i>Advances in Experimental Medicine and Biology</i> , 1998, 451, 315-321. | 0.8 | 7 |
| 137 | Substrate stereochemistry of isovaleryl-CoA dehydrogenase. <i>Bioorganic Chemistry</i> , 1986, 14, 170-175. | 2.0 | 5 |
| 138 | Go, no-go decision making for phase 3 clinical trials: ACT IV revisited " Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710. | 5.1 | 5 |
| 139 | Neurological malignancies in neurofibromatosis type 1. <i>Current Opinion in Oncology</i> , 2019, 31, 554-561. | 1.1 | 5 |
| 140 | Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. <i>Genes</i> , 2020, 11, 671. | 1.0 | 5 |
| 141 | Identification of PTEN-related sequences in glioma cells and in non-neoplastic cell lines. <i>Cancer Letters</i> , 1999, 138, 1-4. | 3.2 | 4 |
| 142 | Gene therapy of glioblastomas: from suicide to homicide. <i>Progress in Brain Research</i> , 2001, 132, 711-719. | 0.9 | 4 |
| 143 | Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2017, 7, 592-597. | 1.1 | 4 |
| 144 | NG2/CSPG4 in glioblastoma: about flexibility. <i>Neuro-Oncology</i> , 2019, 21, 697-698. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | PGE2 Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma. <i>Pharmaceutics</i> , 2020, 12, 215. | 2.0 | 4 |
| 146 | From Standard Treatment to Personalized Medicine: Role of IDH1 Mutations in Low-Grade Glioma Evolution and Treatment. <i>World Neurosurgery</i> , 2010, 73, 234-236. | 0.7 | 3 |
| 147 | Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 0.9 | 2 |
| 148 | Gene Transfer of Suicide Genes for the Treatment of Malignant Gliomas: Efficacy, Limitations, and Perspectives for a Combined Immunotherapy. , 1997, 68, 100-104. | | 2 |
| 149 | Substrate stereochemistry of 2-methyl-branched-chain acyl-CoA dehydrogenase: elimination of one 1986, 873, 308-311. | 2.1 | 1 |
| 150 | The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy. <i>Cytotechnology</i> , 2003, 41, 93-101. | 0.7 | 1 |
| 151 | Milan 2020: COVID-19, neuro-oncology and much more. <i>Journal of Neuro-Oncology</i> , 2020, 148, 201-202. | 1.4 | 1 |
| 152 | Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2087-2087. | 0.8 | 1 |
| 153 | Principi di terapia genica. , 2009, , 593-606. | | 0 |
| 154 | Oligoastrocytomas. , 2011, , 2600-2602. | | 0 |
| 155 | Cancer Stem-Like Cells. , 2014, , 767-771. | | 0 |
| 156 | Cancer Stem-Like Cells. , 2014, , 1-5. | | 0 |
| 157 | Oligoastrocytomas. , 2017, , 3189-3192. | | 0 |
| 158 | Glioblastomas. <i>Cancers</i> , 2022, 14, 104. | 1.7 | 0 |